文献速递乳腺癌

低风险导管原位癌主动监测与治疗的比较:LORD试验中女性偏好

Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
PubMed 文献 · Eur J Cancer · 2023-08-04

LORD试验是一项非随机患者偏好试验,旨在评估低风险导管原位癌(DCIS)主动监测(AS)的安全性,让患者在AS与常规治疗(CT)之间选择。377名女性中76%选择AS,24%选择CT;选择AS的主要原因包括「治疗(尚)不必要」(59%)和信任AS方案(39%),选择CT的主要原因包括担心癌症(51%)和感知确定性(29%)。选择AS的女性教育水平较低(OR 0.45;95%CI 0.22-0.93)和报告共同决策(OR 2.71;95%CI 1.37-5.37)的比例更高。

要点

  • LORD试验中76%低风险DCIS女性选择主动监测,24%选择常规治疗。
  • 选择主动监测最常见原因为认为治疗尚不必要(59%)和信任监测方案(39%)。
  • 选择常规治疗最常见原因为担心癌症(51%)和感知确定性(29%)。

核心结论

  • LORD试验首次为低风险DCIS女性提供常规治疗与主动监测之间的选择,多数女性选择主动监测并对监测安全性高度信任,其偏好凸显建立低风险DCIS主动监测安全性的必要性。

研究设计与样本

  • 非随机患者偏好LORD试验,从基线问卷提取数据,采用描述性统计、主题分析和多变量逻辑回归分析。

主要发现

  • 377名女性中76%选择主动监测,24%选择常规治疗。
  • 选择主动监测的原因包括「治疗(尚)不必要」(59%)和信任主动监测方案(39%)。
  • 选择常规治疗的原因包括担心癌症(51%)和感知确定性(29%)。
  • 选择主动监测的女性教育水平较低(OR 0.45;95%CI 0.22-0.93)和报告共同决策(OR 2.71;95%CI 1.37-5.37)的比例更高。

关键数值与推荐

  • 选择主动监测与较低教育水平相关(OR 0.45;95%CI 0.22-0.93)。
  • 选择主动监测与报告共同决策相关(OR 2.71;95%CI 1.37-5.37)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ductal carcinoma in situ (DCIS) can progress to invasive breast cancer (IBC), but most DCIS lesions remain indolent. However, guidelines recommend surgery, often supplemented by radiotherapy. This implies overtreatment of indolent DCIS. The non-randomised patient preference LORD-trial tests whether active surveillance (AS) for low-risk DCIS is safe, by giving women with low-risk DCIS a choice between AS and conventional treatment (CT). Here, we aim to describe how participants are distributed among both trial arms, identify their motives for their preference, and assess factors associated with their choice. METHODS: Data were extracted from baseline questionnaires. Descriptive statistics were used to assess the distribution and characteristics of participants; thematic analyses to extract self-reported reasons for the choice of trial arm, and multivariable logistic regression analyses to investigate associations between patient characteristics and chosen trial arm. RESULTS: Of 377 women included, 76% chose AS and 24% CT. Most frequently cited reasons for AS were "treatment is not (yet) necessary" (59%) and trust in the AS-plan (39%). Reasons for CT were cancer worry (51%) and perceived certainty (29%). Women opting for AS more often had lower educational levels (OR 0.45; 95% confidence interval [CI], 0.22-0.93) and more often reported experiencing shared decision making (OR 2.71; 95% CI, 1.37-5.37) than women choosing CT. CONCLUSION: The LORD-trial is the first to offer women with low-risk DCIS a choice between CT and AS. Most women opted for AS and reported high levels of trust in the safety of AS. Their preferences highlight the necessity to establish the safety of AS for low-risk DCIS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schmitz RSJM, Engelhardt EG, Gerritsma MA, et al. Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial. Eur J Cancer. 2023. PMID: 37657228. doi:10.1016/j.ejca.2023.113276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。